
REVIEW





Bone marrow chimeras—a vital tool in basic and translational research

Filipa M. Ferreira · Pushpalatha Palle · Johannes vom Berg · Prajwal Prajwal · Jon D. Laman · Thorsten Buch · De Prajwal · John D. Laman · Thorsten Buch · De Prajwal · Prajwal · Jon D. Laman · Thorsten Buch · De Prajwal · De Prajwal · Jon D. Laman · Thorsten Buch · De Prajwal ·

Received: 11 January 2019 / Revised: 26 March 2019 / Accepted: 1 April 2019 / Published online: 26 April 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

Bone marrow chimeras are used routinely in immunology research as well as in other fields of biology. Here, we provide a concise state-of-the-art review about the types of chimerisms that can be achieved and the type of information that each model generates. We include separate sections for caveats and future developments. We provide examples from the literature in which different types of chimerism were employed to answer specific questions. While simple bone marrow chimeras allow to dissect the role of genes in distinct cell populations such as the hematopoietic cells versus non-hematopoietic cells, mixed bone marrow chimeras can provide detailed information about hematopoietic cell types and the intrinsic and extrinsic roles of individual genes. The advantages and caveats of bone marrow chimerism for the study of microglia are addressed, as well as alternatives to irradiation that minimize blood-brain-barrier disruption. Elementary principles are introduced and their potential is exemplified through summarizing recent studies.

Keywords Bone marrow chimeras · Tools · Stem cells · Hematopoiesis · Irradiation damage

Abbreviations

BM Bone marrow

BMC Bone marrow chimera(s) CNS Central nervous system

DC Dendritic cells

EAE Experimental autoimmune encephalomyelitis

GFP Green fluorescent protein
HLA Human leukocyte antigen
HSC Hematopoietic stem cell(s)
ILC Innate lymphoid cells

KO Knockout

MHC Major-histocompatibility complex

TBI Total body irradiation

☐ Thorsten Buch thorsten.buch@uzh.ch

- Institute of Laboratory Animal Science, University of Zurich, Zurich, Switzerland
- ² Benaroya Research Institute at Virginia Mason, Seattle, WA, USA
- Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands
- ⁴ Institute of Laboratory Animal Science, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland

WT Wildtype

Introduction

All immune cell types, as part of the hematopoietic system, undergo constant renewal from hematopoietic stem cells (HSC). This feature is exploited in research by generation and use of bone marrow chimeras (BMC). In this review, we want to introduce the reader into the various applications of BMC in biomedical research and discuss their advantages but also their pitfalls. In contrast to the situation in humans or in most other animal species, the frequent use of inbred mouse strains makes application of BMC for research purposes comparatively easy. Our discussion will thus focus on the mouse, but the concepts can be applied to other species where inbred lines, clones, or identical siblings are available.


As a basic principle, BMC are obtained by transplanting bone marrow (BM) or purified HSC between different subjects. The development of BMC dates back to the middle of the twentieth century. In the aftermath of the second World War and fearing further nuclear conflicts and accidents, there was an increase in medical research towards understanding and treating the consequences of exposure to whole-body irradiation. One of the most affected organs in this context is the



BM. Thus, and contrary to most recent discoveries, BM transplantation has been developed almost in parallel, in animal models as well as human subjects (for a detailed historical perspective of the first 25 years, see the review by Seller in 1970 [1]). Moreover, initial research in animal models was preferentially performed in dogs and other outbred species, since it was acknowledged at the time that inter-subject variability of undetermined factors could negatively affect the success of cell and organ transplantation [2]. As it proved very difficult to identify those factors, experimental animals were chosen in order to mimic the human situation. Initial studies in mice date back to 1949 when Jacobson and colleagues showed that shielding the spleen of mice with lead allowed them to survive otherwise lethal whole-body irradiation [3]. Yet, at that time, the nature of this protection remained unclear: was it dependent on humoral factors or was it cellular reconstitution? In 1956, Ford and colleagues used basic chromosome size and morphology to show that protection against irradiation was mediated by repopulation through donor cells [4]. These initial reports paved the way for the BM transplantation field, a field intimately linked to leukemia treatment and graft versus host disease. Accordingly, in 1956, Barnes and Loutit showed that mice can be treated for leukemia by irradiation followed by transplantation of normal mouse BM [5]. These studies were translated to humans by Thomas and colleagues who soon realized that only transplants of syngeneic BM, such as those from identical twins, were successful [6, 7]. From then on, transplantation in the human developed into a routinely used treatment for various diseases such as malignancies, autoimmune disorders, and germline mutations. A parallel interest in using BMC as a tool for basic and translational research developed. One prominent example of such studies is the work of Spangrude et al., published in 1988, describing the procedure of isolating mouse HSC and establishing phenotypic markers [8]. Currently, the use of BMC in research is widespread and different approaches have been developed that allow for a higher resolution in the analysis of different cell types and of gene functions, as discussed below and summarized in Fig. 1.

Generating BMC

The first step in the generation of BMC is to remove the host hematopoietic system. Usually, this is achieved by exposing the animals to full-body gamma irradiation. DNA double strand breaks will lead to induction of cell death especially in rapidly dividing compartments such as HSC and other immune cell precursors. In mice, this cell ablation can be achieved by irradiating with a total of 9–12 Gy in 1 continuous cycle [9] or 2 cycles of 5.5–7 Gy with an interval of 3–4 h [10] for attenuation of side effects. An alternative to irradiation is chemical conditioning by use of busulfan [11, 12]. Ablation of



The second step is to transplant the HSC or complete BM cells into the host by intravenous injection, or alternatively by intraperitoneal injection, albeit at lower efficacy [13]. Successful generation of BMC depends on several factors such as the histocompatibility between the host and donor, the secondary effects of the irradiation protocol, the presence of pathogens, and the age of both donor and host animals. Histocompatibility issues were the reason why so many studies have failed in the early days of BM transplantation, when the existence of polymorphisms in major-histocompatibility complex (MHC) genes, the human leukocyte antigen (HLA) and the mouse H-2 antigens, were not known. Irradiation itself can cause gastrointestinal dysfunction as the gut is the site of a large population of highly proliferative epithelial cells directly affected by the induction of double strand DNA breaks [14]. Moreover, the lack of a functional immune system can give rise to opportunistic infections, such as by Pseudomonas aeruginosa, which is a major cause of death in irradiated mice. Hence, irradiated mice must be given antibiotics for at least 2 weeks post-irradiation to avoid opportunistic infections [15]. Even though many scientists prefer to obtain BMC by use of individuals of identical sex or even only among females [10], sex mismatch was for some used as marker for determining chimerism (for example, [16]). There are, however, indications of problems associated with a sex mismatch [17]. Good protocols for optimized procedures to obtain BMC are given by Spangrude [10] as well as by Duran-Struuk and Dysko [18].

Timeline of immune reconstitution

After transplantation of the BM, immune system reconstitution is self-propagating, with different immune lineages repopulating with individual time courses. In mice, full






Fig. 1 Summary of the BMC tools used in research. First row, simple BMC. Second row, simple BMC with head-shield (green)—immune resident cells are not ablated from the central nervous system. Third row, mixed BMC (1:1 ratio)—half of the immune cells of the chimeric

mice are knockout (KO). Fourth row, complex mixed BMC (1:4 ratio)—wherein all T and B cells from the chimeric mice are KO, only 20% of the myeloid compartment is KO. Legend: KO knockout, WT wildtype, RAG Rag1 or Rag2 deficient mice that lack mature T and B cells

reconstitution takes around 8 weeks. The first lineages to be quantitatively fully reconstituted are the myeloid cell types, then macrophages, polymorphonuclear cells, and dendritic cells (DC), which are back after just 1 week after the transfer. They are followed by natural killer cells (week 2), B cells (week 3), and T cells (week 8) [19, 20]. Two points are of note: A) upon repopulation, all immune cell subsets overshoot their normal absolute cell counts and stabilization takes considerably longer than repopulation (Fig. 2, [19, 20]) and B) quantitative reconstitution is not always followed immediately by re-establishment of all cellular functions. Whereas DC appear to be fully functional after regaining their population size, NK cells only become fully functional 1 week after achieving full quantitative reconstitution as was found by correlation of cytokine production with reconstitution [20]. Taken together, for a fully functional immune reconstitution after BMC, host animals should be given at least 8 weeks of recovery time.

BMC for the study of gene function in hematopoietic versus non-hematopoietic cells

In its most simple application, BMC allow to identify the functional consequences of a gene modification to either an irradiation-sensitive cell type, usually hematopoietic, or an irradiation-resistant cell type, usually non-hematopoietic. A plethora of studies have made use of this technique. Here we chose to highlight five recent exemplary studies conveying the experimental design behind the different BMC experiments. As the first example, we want to highlight the merits of a simple BMC experiment using a gene deficiency by summarizing the study of Kreymborg and colleagues [21]. In this

study, the role of B7.H3 in the development of spontaneous prostate cancer in mice was assessed. BMC allowed the researchers to determine that tumor growth was controlled by the presence of B7.H3 on non-hematopoietic cells (Table 1). The authors determined chimerism in their experiments by use of CD45.1/CD45.2 congenic system. This study also presents all the appropriate groups and controls that should be run in such a BMC experiment. Transplantation of gene-modified BM into wildtype and of wildtype BM into gene-modified animals allows to identify the effect distinguishing hematopoietic versus non-hematopoietic cell types. The two other types of chimeras, wildtype into wildtype and mutant into mutant, serve as controls for effects of the BMC procedure per se on cells and organism on wildtype or gene-modified genetic background.

Mixed BMC for the study of cell type intrinsic vs extrinsic effects of a gene modification

When cells from different genotypes develop under identical conditions within the same individual, any difference observed between them regarding proliferation and differentiation is most likely cell-intrinsic. This can be achieved and exploited in mixed BMC. They allow to determine whether effects of a gene modification are extrinsic or intrinsic within the investigated hematopoietic cell type. Such mixed BMC are generated by, for instance, transplanting the BM of wildtype and that of genetically modified donors in equal proportions into irradiated recipients. This concept was used in the second example study, in which the intrinsic capability of T cells as IL-23-mediated driver of GM-CSF production was identified [22]. Here, the *Rag1*-deficient host precluded







Fig. 2 Timeline of immune reconstitution after BM transplantation in the mouse. This figure is based on [19, 20]). Legend: TBI total body irradiation

interference from surviving host T and B cells. Donor 1 was wildtype while the cells from donor 2 were deficient for one or the other IL-12 receptor subunit. As these receptors are solely expressed on T and not on B cells, the donor cells were a mix of fully functional B cells (from donor 1 and donor 2) and a mix of T cells in which half of them (from donor 2) were selectively incapable to respond to IL-12 + IL-23, or IL-12 alone (Table 2).

Mixed BMC can also be used to assess the effect of extrinsic factors on the differentiation of two cell populations from different donors in parallel in the same organism. In the third exemplary study, mixed BMC was used to assess the factors underlying impaired NK cell function during aging. Shehata and colleagues addressed the consequences of having NK cells derived from BM of young (CD45.1) and aged (CD45.2) mice transferred into both young and aged host mice [23]. The results suggest that aged NK cells are fully functional provided that the non-hematopoietic environment in which they reside is juvenile. Conversely, NK cells from young donors are not able to fully exert their functions when transferred into an old host. Hence, this study highlights the importance of the microenvironment in cellular function and may impact therapy approaches to NK cell impairment disorders.

Complex mixed BMC to study the role of an individual gene in a particular cell type

An even more complex BMC approach allows the restriction of gene deficiencies to specific hematopoietic subpopulations. For this experimental design, BM from two donors are needed, one of them lacking the genetic ability to generate a certain



For more analytical specificity, BM from JhT [25, 26] or μMT [27] animals can be used for analysis of the B cell compartment, and BM from Terb-deficient animals [28] for analysis of the T cell compartment. Whenever a factor is known whose absence leads to a block in the development of the cell type in question, the respective BM can be used for experiments with unequal ratios. Two examples of this usage are studies using different B cell deficient mice to provide insight into the function of IL-10 in the B cell lineage: 1) using JhT mice in a mixed chimerism setting. Stein and colleagues were able to exclude immunomodulation caused by the production of IL-10 by B cells as the players behind the mechanism of action of transcutaneous immunization [29]; whereas 2) Fillatreau studied the role of IL-10 producing B cells in the recovery remission phase of experimental autoimmune encephalomyelitis (EAE). Using µMT mice to generate mixed chimeras that lack the production of IL-10 in B cells, the authors observed more severe and non-remitting EAE progression than in the control mice [30].

Such lineage-specific BMC may also be obtained by toxinmediated ablation of a specific cell lineage through use of, for instance, diphtheria toxin A or its receptor. BM from such mice can be used as donor 2, in order to restrict the gene deficiency to the cell type of interest.

BMC for the study of peripheral and CNS myeloid cells

Within the central nervous system (CNS), BMC studies are very useful in distinguishing microglia, the yolk-sac-derived phagocyte of the CNS, from infiltrating macrophages. Here, the crucial factor is that only the healthy, undisturbed CNS shows a very



Table 1 Experimental design and major findings using simple BMC. This study aimed to assess whether the role of B7.H3 in tumor progression is mediated by its expression in the hematopoietic system or rather in non-hematopoietic tissue. Therefore, the authors used a simple BMC design with four groups: group 1 is deficient for B7.H3 only in tissue due to transplant of wildtype HSC into B7.H3 knockout mice. Group 2 is the control, in which wildtype cells are transferred to wildtype mice. Group 3 is fully deficient for B7.H3 as knockout HSC were introduced into knockout mice. Group 4 is deficient for B7.H3 in the immune compartment. As wildtype recipients have similar tumor sizes whereas recipients deficient for B7.H3 have larger tumor sizes, regardless of the type of cells transplanted, the authors conclude that stromal B7.H3 expression is regulating tumor development. [21]

Donor	Recipient	B7.H3 deficiency	Tumor size
Wildtype CD45.1	B7.H3 KO CD45.2	Tissue	Larger
	B7.H3 WT CD45.2	None, wildtype situation	Control
B7.H3 KO CD45.2	B7.H3 KO CD45.1	Tissue and hematopoietic cells, full knockout situation	Larger
	B7.H3 WT CD45.1	Hematopoietic cells	As control

low level of surveillance by immune cells other than microglia. This feature of the CNS should be preserved so that only brainresident cells from the host are present at the time of transplantation and no contamination with blood-derived cells into the CNS has taken place. To achieve this, the recipient mice can be head-shielded with a lead cover during irradiation. In our fifth and last example, Mildner and colleagues assessed the role of monocytes in a transgenic mouse model for Alzheimer's disease, by directly comparing whole-body irradiation with head shielding [31]. For identification of resident versus infiltrating macrophages, GFP-labeled BM cells were used instead of a congenic marker. One of the main findings of this study is that exposing the brain to irradiation has consequences to the resident cell population that could bias study conclusions. It should either be avoided or controlled for. An alternative to head-shield is the use of busulfan instead of irradiation for conditioning [32, 33]. Another possibility for populating the brain with a

Table 2 Experimental design and major findings using mixed BMC to study the relationship between IL-23 signaling in T cells and GM-CSF production. The authors adopted a mixed BMC scheme by cotransplanting in a 1:1 ratio wildtype HSC and HSC in which T cells lack the β1 subunit of IL12R (first row), T cells lack the β2 subunit of

haematopoietically derived cell types of interest is intranasal administration of HSC [34]. This technique bypasses the need to ablate the BM, thus shortening the process and decreasing adverse side effects. Yet, engraftment appears to be somewhat less effective than after conventional BMC.

Caveats of using BMC

Box 1 Factors affecting the success of bone marrow chimeras. To successfully generate BMC, the immune system of the recipient mice must be first depleted and then reconstituted in a fashion that does not trigger major adverse side effects. Hence, several factors should be taken into consideration

Radiation doses	Irradiating mice two times with a lower dosage, over a time period around 7 h, allows for a better ablation of the recipient hematopoietic compartment than a one-time irradiation protocol. It also reduces gastrointestinal side effects.
Mouse strain and detection markers	GFP expression in mice can lead to an anti-GFP response that can affect the detection rates of this marker. The magnitude of this response differs from strain to strain. CD45.1 cells have a slower rate to full immune compartment reconstitution than CD45.2 cells.
Gut microbiota	The decrease of gut microbiota diversity due to antibiotics use can impact the success rate of BMC, as gut bacteria produce metabolites that are required for appropriate development of certain leukocyte lineages.

Although a highly useful tool for a variety of questions, BMC are obviously not free of limitations. They should be used solely in carefully controlled experimental designs and the researcher should be aware of its caveats. One such caveat is the use of allotypes (e.g., CD90.1 vs CD90.2) and fluorescent proteins to track the donor cells in the recipient mice. Depending on exact experimental circumstances, these molecules may be a target of an immune response. This was highlighted in studies in which tumor cells expressing an allotype (CD90.1) or fluorescent protein (eGFP) were

the same receptor (second row), or fully express both subunits (third row). These mixtures were transplanted into *Rag1* mice, which lack T and B cells. Therefore, the authors could assess production of GM-CSF when T cells are differentially able to respond to IL-12 and IL-23, concluding that GM-CSF production is mainly regulated by IL-23. [22]

Donor 1	Donor 2	Recipient	IL-23 response	GM-CSF production
Wildtype CD45.2	$Il12r2\beta I$ KO (T cells do not respond to IL23 + IL12) $Il12r2\beta 2$ KO (T cells do not respond to IL12) Wildtype (fully responsive)	Rag1 CD45.1	Halved As control Control	Decreased Increased Control




Table 3 Experimental design and major findings using complex mixed BMC for studying the role of IL-18R within the lymphoid compartment in EAE development. Gutcher et al. transplanted a mix of BM from *Il18r*-deficient (20%) and *Rag1*-deficient (80%) mice into wildtype recipients. Hence, all lymphoid cells were derived from the Il18r-deficient BM (as *Rag1* do not have mature T and B cells), whereas the myeloid cells were mostly derived from the *Rag1*-deficient, *Il18r*-sufficient BM. By diluting the myeloid compartment to 20% of knockout cells, the authors reduced its influence in EAE progression and were able to observe that a deficient IL-18 response in T and B cells leads to reduced EAE severity. [24]

Donor 1	Donor 2	Recipient	Il18r1 deficiency	EAE
Wildtype ####################################	- - Rag1 4 parts	Wildtype Wildtype Wildtype	None Hematopoietic cells T/B cells	Control As control Reduced

transplanted into donor mice expressing the other allotype (CD90.2) or wildtype background, respectively. These experiments showed that both factors are capable of triggering an immune response [35–37]. It should be kept in mind that mouse strains are differentially capable of mounting immune responses to certain tracking molecules, with BALB/c mice being more immunocompetent against eGFP than C57BL/6 [38]. Finally, whereas CD45.2 cells transferred into CD45.1 expressing mice result in full reconstitution of the immune system, transplanting CD45.1 expressing cells into CD45.2 mice results in a reduction in the numbers of cells contributing to the long-term reconstitution of the immune system, due to lower homing capabilities of CD45.1 expressing cells [39].

Another issue with BMC is the effect of whole-body irradiation. We discussed above the effects on mucosal tissue of the gut, but other organ systems are also affected. From humans, it is known that at doses close to LD₅₀, the principal symptoms of the prodromal syndrome are anorexia, nausea, vomiting, and easy fatigability. Immediate diarrhea, fever, or hypotension indicates a supralethal exposure. In mice, the effect of irradiation on the skin is usually easily visible when black-haired recipients are used: it leads to graying of the coat. In humans, a dose as low as 0.15 Gy leads to temporary sterility in men and may induce symptomatic pneumonitis (forced breathing, inadequate gas exchange) in 5% of people [40]. Researchers should check for these symptoms after the irradiation cycles of the BM transplantation procedure. Lethal cerebrovascular syndrome is seen in humans following high-dose irradiation (> 100 Gy); small non-lethal effects on the CNS at lower doses should be therefore kept in mind. Another issue with BMC is the effect of irradiation in depleting the mucosal tissue from immune cells [41]. The reconstitution of the immune system occurs within each cell niche. Thus, while primary and secondary lymphoid organs may be completely repopulated by donor cells after irradiation, the same is not necessarily true for the mucosa. Complete ablation of immune cells by irradiation of the intestinal mucosa may not be achieved with the protocols



Future developments

Now well into their sixties, BMC have come of age, and clearly will remain a major and highly valuable technological tool. Their applications are being and will be further extended by optimal integration of established and novel technologies. For instance, repertoire sequencing of T and B cells is highly informative and CRISPR-Cas techniques are finding their way into BMC. Highly sophisticated imaging technology of individual cells in vivo will be useful to assess issues like competitive advantage of individual cells upon transfer in relation to tissue niches [49]. Finally, emerging technologies in DNA writers and molecular recorders will provide new opportunities for cell tracing and in vivo functionality [50].



Acknowledgments Carla Rohrer-Bley supported us with her expertise in radiation biology. Work in the lab of Jon Laman is supported by the Dutch MS Research Society and the Zabawas foundation. Work in the lab of Thorsten Buch was supported by the Swiss MS Society and the Hertie Foundation. Work in the lab of Johannes vom Berg was supported by Swiss Cancer Research and the Novartis foundation for medical-biological research. Dr. Prajwal is supported by the UZH Entrepreneur-Fellowship in BioTech and MedTech.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

- Seller MH (1970) Animal models for bone-marrow transplantation. J Med Genet 7(4):305–309
- Main JM, Prehn RT (1955) Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst 15(4):1023–1029
- Jacobson LO, Simmons EL, Marks EK, Robson MJ, Bethard WF, Gaston EO (1950) The role of the spleen in radiation injury and recovery. J Lab Clin Med 35(5):746–770
- Ford CE, Hamerton JL, Barnes DW, Loutit JF (1956) Cytological identification of radiation-chimaeras. Nature 177(4506):452–454
- Barnes DW, Loutit JF (1957) Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol 3(3):241– 252
- Thomas ED, Lochte HL Jr, Cannon JH, Sahler OD, Ferrebee JW (1959) Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 38:1709–1716
- Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257(11):491–496
- Spangrude GJ, Heimfeld S, Weissman IL (1988) Purification and characterization of mouse hematopoietic stem cells. Science (New York, NY) 241(4861):58–62
- Down JD, Tarbell NJ, Thames HD, Mauch PM (1991) Syngeneic and allogeneic bone marrow engraftment after total body irradiation: dependence on dose, dose rate, and fractionation. Blood 77(3): 661–669
- Spangrude GJ (2008) Assessment of lymphocyte development in radiation bone marrow chimeras. Curr Protoc Immunol Chapter 4: Unit 4.6
- Floersheim GL, Elson LA (1961) Restoration of hematopoiesis following a lethal dose of dimethyl myleran by isologic bone marrow transplantation in mice. Experiments on modification of intolerance to homologous bone marrow by 6-mercaptopurine, aminochlorambucil and cortisone. Acta Haematol 26:233–245
- Peake K, Manning J, Lewis CA, Barr C, Rossi F, Krieger C (2015) Busulfan as a myelosuppressive agent for generating stable highlevel bone marrow chimerism in mice. J Vis Exp: JoVE (98): e52553. https://doi.org/10.3791/52553
- Fiala J (1970) On the transplantability of cadaver bone marrow. In vivo determination of the viability of mouse bone marrow cells. Physiol Bohemoslov 19(5):441–445
- Friedman NB (1945) Cellular dynamics in the intestinal mucosa: the effect of irradiation on epithelial maturation and migration. J Exp Med 81(6):553–558
- Wolf N, Stenback W, Taylor P, Graber C, Trentin J (1965) Antibiotic control of post-irradiation deaths in mice due to Pseudomonas aeruginosa. Transplantation 3:585–590

 Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, Neutzel S, Sharkis SJ (2001) Multi-organ, multilineage engraftment by a single bone marrow-derived stem cell. Cell 105(3):369–377

- Psottova J (1989) Proof of radiation chimera by means of chromosomal analysis. Acta Univ Carol Med 35(3–4):179–185
- Duran-Struuck R, Dysko RC (2009) Principles of bone marrow transplantation (BMT): providing optimal veterinary and husbandry care to irradiated mice in BMT studies. J Am Assoc Lab Anim Sci: JAALAS 48(1):11–22
- Chen BJ, Cui X, Sempowski GD, Domen J, Chao NJ (2004) Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 103(11):4344– 4352
- Auletta JJ, Devecchio JL, Ferrara JL, Heinzel FP (2004) Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 10(12):834–847
- Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G, Savage PA, van den Brink MR, Allison JP (2015) Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer Immunol Res 3(8):849–854
- Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B (2011) RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12(6):560–567
- Shehata HM, Hoebe K, Chougnet CA (2015) The aged nonhematopoietic environment impairs natural killer cell maturation and function. Aging Cell 14(2):191–199
- Gutcher I, Urich E, Wolter K, Prinz M, Becher B (2006) Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol 7(9):946–953
- Gu H, Zou Y-R, Rajewsky K (1993) Independent control of immunoglobulin switch recombination at individual switch regions evidenced through cre-loxP-mediated gene targeting. Cell 73:10
- Gu H, Zou YR, Rajewsky K (1993) Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73(6): 1155–1164
- Kitamura D, Roes J, Kuhn R, Rajewsky K (1991) A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350(6317):423–426
- Mombaerts P, Clarke AR, Hooper ML, Tonegawa S (1991) Creation of a large genomic deletion at the T-cell antigen receptor beta-subunit locus in mouse embryonic stem cells by gene targeting. Proc Natl Acad Sci U S A 88(8):3084–3087
- Stein P, Weber M, Prufer S, Schmid B, Schmitt E, Probst HC, Waisman A, Langguth P, Schild H, Radsak MP (2011) Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization. PLoS One 6(11):e27911. https://doi.org/10.1371/journal. pone.0027911
- Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3(10):944–950
- Mildner A, Schlevogt B, Kierdorf K, Bottcher C, Erny D, Kummer MP, Quinn M, Bruck W, Bechmann I, Heneka MT (2011) Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci 31(31):11159–11171
- Kierdorf K, Katzmarski N, Haas CA, Prinz M (2013) Bone marrow cell recruitment to the brain in the absence of irradiation or parabiosis bias. PLoS One 8(3):e58544. https://doi.org/10.1371/journal. pone.0058544



 Lewis CA, Manning J, Barr C, Peake K, Humphries RK, Rossi F, Krieger C (2013) Myelosuppressive conditioning using busulfan enables bone marrow cell accumulation in the spinal cord of a mouse model of amyotrophic lateral sclerosis. PLoS One 8(4): e60661. https://doi.org/10.1371/journal.pone.0060661

- Sun J, Wei ZZ, Gu X, Zhang JY, Zhang Y, Li J, Wei L (2015) Intranasal delivery of hypoxia-preconditioned bone marrowderived mesenchymal stem cells enhanced regenerative effects after intracerebral hemorrhagic stroke in mice. Exp Neurol 272:78–87
- Skelton D, Satake N, Kohn DB (2001) The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther 8(23):1813–1814
- McKenna KC, Vicetti Miguel RD, Beatty KM, Bilonick RA (2011)
 A caveat for T cell transfer studies: generation of cytotoxic anti-Thy1.2 antibodies in Thy1.1 congenic mice given Thy1.2+ tumors or T cells. J Leukoc Biol 89(2):291–300
- Ansari AM, Ahmed AK, Matsangos AE, Lay F, Born LJ, Marti G, Harmon JW, Sun Z (2016) Cellular GFP toxicity and immunogenicity: potential confounders in in vivo cell tracking experiments. Stem Cell Rev 12(5):553–559
- Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D (1999) Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 6(7):1305–1312
- Waterstrat A, Liang Y, Swiderski CF, Shelton BJ, Van Zant G (2010) Congenic interval of CD45/Ly-5 congenic mice contains multiple genes that may influence hematopoietic stem cell engraftment. Blood 115(2):408–417
- Hall EJ, Giaccia AJ (2012) Radiobiology for the radiologist (seventh edition), 7th edition edn. Wolters Kluwer Health/Lippincott Williams & Wilkings, Philadelphia PA
- Staley EM, Tanner SM, Daft JG, Stanus AL, Martin SM, Lorenz RG (2013) Maintenance of host leukocytes in peripheral immune compartments following lethal irradiation and bone marrow reconstitution: implications for graft versus host disease. Transpl Immunol 28(2–3):112–119
- Vermijlen D, Prinz I (2014) Ontogeny of innate T lymphocytes some innate lymphocytes are more innate than others. Front Immunol 5:486. https://doi.org/10.3389/fimmu.2014.00486

- van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D (1974) Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 52(2):401–404
- Mathewson ND, Jenq R, Mathew AV, Koenigsknecht M, Hanash A, Toubai T, Oravecz-Wilson K, Wu SR, Sun Y, Rossi C (2016) Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17(5):505–513
- Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, Ling L, Kosuri S, Maloy M, Slingerland JB (2017) Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol 35(15):1650–1659
- 46. Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J et al (2016) Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 8(339):339–371
- Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ (2018) Clinical application and potential of fecal microbiota transplantation. Annu Rev Med 70:335–351
- 48. Hui S, Takahashi Y, Holtan SG, Azimi R, Seelig D, Yagi M, Ingvalson J, Alaei P, Sharkey L, Kodal B, Peterson N, Meyer C, Godin L, Ehrhardt M, Storme G, Zhou D, Panoskaltsis-Mortari A (2017) Early assessment of dosimetric and biological differences of total marrow irradiation versus total body irradiation in rodents. Radiother Oncol 124(3):468–474
- Liu TL, Upadhyayula S, Milkie DE, Singh V, Wang K, Swinburne IA, Mosaliganti KR, Collins ZM, Hiscock TW, Shea J (2018)
 Observing the cell in its native state: imaging subcellular dynamics in multicellular organisms. Science (New York, NY) 360(6386). https://doi.org/10.1126/science.aaq1392
- Farzadfard F, Lu TK (2018) Emerging applications for DNA writers and molecular recorders. Science (New York, NY) 361(6405):870– 875

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

